65,437 trials
Head and Neck Cancer
Primary: Maximum Tolerated Dose (MTD) of Metformin in Combination With Concurrent Cisplatin and Radiation — NA; NA; NA mg
Dry Eye
Primary: Subjective Ocular Symptoms — 27.42; 27.43 score on a scale
Colitis, Ulcerative
Primary: Part A: Number of Participants With Common (>=5%) Non-serious Adverse Events (Non-SAEs) and Any Serious Adverse Events (SAEs) — 7; 13; 1; 0 Participants
Congenital Fibrinogen Deficiency
Primary: Overall Clinical Assessment of the Haemostatic Efficacy of Octafibrin in the On-demand Treatment of the First Documented Bleeding Episode of Each Patient Based on a…
Inguinal Hernia
Primary: Ingrowth of Newly Formed Nervous Elements Within Hernia Implant ProFlor — 999.75; 1044; 2094 μm^2 — p=0.028
Dengue Fever · Dengue Hemorrhagic Fever · Human Papillomavirus Disease
Primary: Geometric Mean Titers (GMTs) Against Each Gardasil Vaccine Human Papillomavirus (HPV) Antigen (HPV-6, HPV-11, HPV-16, HPV-18) 28 Days After Last Gardasil Vaccination in…
Tympanic Membrane Perforation
Primary: Number of Patients With Tympanic Membrane Closure Following Treatment — 23; 10 Participants
Acne Vulgaris
Primary: Absolute Change in the Inflammatory Lesion Counts on the Face — 29.4; 29.7; 15.9; 18.2 Lesions
Mild Cognitive Impairment
Primary: Auditory Memory Attention Index — 89.0; 94.3 standard score units — p=<0.01
Social Anxiety Disorder
Primary: Social Anxiety Symptom Severity — -.46; -.90; -.39; -.88 score on a scale — p=<.001
Influenza
Primary: Absolute Vaccine Efficacy (VE) of aQIV Versus Non-influenza Comparator Based on RT-PCR-confirmed Influenza Due to Any Strain Using Protocol Defined ILI Definition…
Pulmonary Arterial Hypertension
Primary: Maximum Tolerated Dose (MTD) of BPS-MR in Pulmonary Arterial Hypertension (PAH) Patients, Following Chronic, Twice-daily Administration. — 2; 2; 3; 2 Participants
Diabetes Mellitus, Type 1
Primary: Time <70 mg/dl by CGM — 4.0; 2.2 percentage of time — p=<0.0001
Diabetic Peripheral Neuropathy
Primary: Numeric Rating Scale (NRS) Average Pain Intensity — -1.50; -1.61; -1.15; -1.23 score on a scale
Endometrial Neoplasms
Primary: Progression Free Survival (PFS) — 3.7; 5.6; 2.1; 2.0 months — p==0.178